Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Heatmap
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
X
XBI
State Street SPDR S&P Biotech ETF
136.2
0
USD
+9917.65%
Sektor:
Finanzen
Basis:
USD
Gewinnwährung:
USD
Tagesspanne
Jahresspanne
Tagesänderung
+9917.65%
Monatliche Änderung
+5.17%
6 month change
+11.88%
Jahresänderung
+23.67%
Vorheriger Schlusskurs
1.3
6
Open
136.4
8
Tief
136.1
5
High
136.7
3
Volumen
649
Märkte
US ETFs
XBI
Vollständige Grafik anzeigen
Full chart
Übersicht
Alle Anlagen
Heatmap
Top-Positionen
Market Value
Shares
Weight %
NBIX
Neurocrine Biosciences Inc
88.32 M
622.68 K
1.13%
CRSP
CRISPR Therapeutics AG
88.24 M
1.68 M
1.12%
ACAD
ACADIA Pharmaceuticals Inc
88.22 M
3.30 M
1.12%
GRAL
GRAIL Inc
87.37 M
1.02 M
1.11%
SMMT
Summit Therapeutics Inc
83.85 M
4.79 M
1.07%
ARQT
Arcutis Biotherapeutics Inc
83.24 M
2.87 M
1.06%
BEAM
Beam Therapeutics Inc
81.67 M
2.95 M
1.04%
MLYS
Mineralys Therapeutics Inc
77.33 M
2.13 M
0.99%
NUVL
Nuvalent Inc
76.99 M
765.39 K
0.98%
DYN
Dyne Therapeutics Inc
76.19 M
3.90 M
0.97%
KYMR
Kymera Therapeutics Inc
76.02 M
977.05 K
0.97%
A
ACLX
Arcellx Inc
75.50 M
1.16 M
0.96%
S
SLNO
Soleno Therapeutics Inc
73.74 M
1.59 M
0.94%
CGON
CG oncology Inc
72.96 M
1.76 M
0.93%
IDYA
Ideaya Biosciences Inc
72.77 M
2.11 M
0.93%
VERA
Vera Therapeutics Inc
72.41 M
1.43 M
0.92%
APLS
Apellis Pharmaceuticals Inc
71.75 M
2.86 M
0.91%
SRPT
Sarepta Therapeutics Inc
69.62 M
3.24 M
0.89%
COGT
Cogent Biosciences Inc
65.74 M
1.85 M
0.84%
RXRX
Recursion Pharmaceuticals Inc
65.66 M
16.05 M
0.84%
1
2
3
4
5
6
7
8
Nachrichten
First Quarter Earnings: Sharpening Sector Divergence
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
3 Reasons To Stick With Growth Stocks In Rotating Markets
Seeking Innovation Beyond Tech? Insight On Healthcare Stocks
Biotech Investors Are Tuning Out the MAHA Chaos
Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)
Capricor: B. Riley bestätigt Kursziel von 63 US-Dollar angesichts von FDA-Fortschritten
FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint
Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)
Mizuho senkt Kursziel für Immunocore wegen Umsatzprognose auf 34 Dollar
What's The Dominant Trend In Earnings: AI Or Geopolitics?